The French Supreme Administrative Court annuls a State’s decision discriminating the reimbursement’s rate between princeps and generic drugs (GlaxoSmithKline)

1. The Regulatory Context: positive discrimination as a starting point and the TFR a possible end to it Sales of reimbursable medicines to consumers are heavily regulated in France, from the level of the pharmaceutical company manufacturing them all the way through to the ultimate individual purchaser, via wholesalers and pharmacists. Before marketing a drug, any pharmaceutical company manufacturing princeps will have to negotiate its public retail prices (and reimbursement level) with the public authorities [1] ; on the other hand, a pharmaceutical company manufacturing generics will have its prices automatically accepted provided that these prices are at least 30-40% lower than the princeps' price. Hence, the first generics to penetrate a "market" where a patent has expired are

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Olivier Fréget, Fleur Herrenschmidt, The French Supreme Administrative Court annuls a State’s decision discriminating the reimbursement’s rate between princeps and generic drugs (GlaxoSmithKline), 11 June 2007, e-Competitions June 2007, Art. N° 13770

Visites 4263

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues